Glioblastoma multiforme (GBM) is a WHO grade IV glioma, that is characterized by its aggressive growth, high invasiveness, and poor clinical outcomes. Despite the current standard of care treatments -surgical resection, radiotherapy, and first-line chemotherapy with temozolomide- the median survival remains only 12–17 months, with a 5-year survival rate of approximately 7%. GBM tumors defined by significant molecular heterogeneity, elevated mutational burden, and presence of therapy-resistant cancer stem cells. Thus, there is an urgent need for innovative, multi-targeted therapeutic strategies. Recent research highlighted the potential of non-coding RNAs, particularly microRNAs, to regulate multiple oncogenic pathways simultaneously. Our analyses of the Rembrandt patient dataset identified three significantly overexpressed key oncogenic signaling molecules (eEF2K, AXL, and FOXM1) in GBM patient tumors and in GBM cell lines. To therapeutically target these drivers, we utilized miRNA-Target gene prediction algorithms and identified three candidate miRNAs with predicted direct binding affinity. We demonstrated, for the first time, that miR-329-5p, miR-449-5p and miR-518c negatively regulate eEF2K, AXL, FOXM1 oncogenes and effectively downregulate their expression. Furthermore, we performed colony formation, wound healing(scratch), invasion(transwell) and 3D spheroid formation assay to evaluate the effects of the candidate miRNAs on cellular proliferation, metastatic potential, and stemness characteristics of GBM. Simultaneously or combined targeting of eEF2K, AXL, FOXM1 oncogenic molecules by each of the miRNAs(miR-329-5p, miR-449-5p, or miR-518c) led to suppression of GBM cell proliferation, migration, invasion, spheroid formation and induced both apoptosis and ferroptosis. Importantly, the combination of these miRNAs with temozolomide produced synergistic anti-proliferative effects in vitro. Moreover, in vivo once a week systemic treatment with miR-329-3p(0.15 mg/kg) incorporated in single lipid nanoparticle significantly suppressed eEF2K, AXL, FOXM1 expression and tumor growth in LN229 GBM xenograft tumor model in mice. These findings support the therapeutic potential of miRNA-based interventions as a multi-targeting strategy, either as monotherapy or in combination with current chemotherapeutics, for more effective management of glioblastoma.